Trial record 12 of 42 for:    " September 30, 2009":" October 30, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy

This study has been completed.
Sponsor:
Collaborator:
Adaptimmune
Information provided by (Responsible Party):
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00991224
First received: October 6, 2009
Last updated: February 20, 2014
Last verified: February 2014
  Purpose

This research study is being carried out to study a new way to possibly treat HIV. T‐cells are one of the white blood cells used by the body to fight HIV. CD8 T‐cells are a type of T‐cell used by the body to detect and kill cells which have been infected by foreign viruses or organisms, including the HIV virus. CD8 T‐cells must identify the HIV virus in order to kill it. Because HIV is constantly changing the way it looks to the CD8 T‐cells, some of the HIV virus escapes detection and is not killed by the CD8 T‐cells.

This research study uses a T cell receptor (TCR) protein specific for HIV (SL9 TCR) and adds it to the CD8 T‐cells in the laboratory in order to help the CD8 T‐cells recognize the constantly changing HIV virus and make it able to fight HIV more efficiently. TCR stands for T cell receptor. TCRs are found on the surface of T cells and allow the T cells to recognize other cells. Laboratory studies have shown that when CD8 T‐cells are modified with SL9 TCRs, they kill cells that are infected with HIV better than normal CD8 T‐cells can. On the basis of these laboratory results, there is the potential that SL9 TCRs may work in people infected with HIV and improve their immune system by killing HIV infected cells and thus may help control HIV infection.

Two different SL9 TCRs will be tested in this study, WT‐gag‐TCR and α/6‐gag‐TCR. Two different types of SL9 TCRs are being used in this research study because the laboratory studies suggest that the different SL9 TCRs will function differently depending on the amount of virus in your body. A goal of this clinical study is to test the effects of infusions of either SL9 TCR in the presence or absence of a viral load.

All subjects who receive WT‐gag‐TCR or the α/6‐gag‐TCR T cells will be enrolled in a Long Term Follow up study to monitor subjects. Subjects will be followed every 6 months for five years following the 1st infusion of the T cells. If the WT‐gag‐TCR or the α/6‐gag‐TCR T cells are no longer found in the blood after five years, then subjects will be contacted yearly for the next 10 years. If the WT‐gag‐TCR or the α/6‐gag‐TCR T cells are found in the blood at five years after the 1st infusion of T cells, then the subjects will continue to be seen once a year until the WT‐gag‐TCR or the α/6‐gag‐TCR T cells are no longer found in the blood for a maximum of 15 years.


Condition Intervention Phase
HIV Infections
Biological: WT-gag-TCR modified T cells
Biological: α/6-gag-TCR modified T cells
Other: STI or Drug Holiday
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Pilot, Open Label, Multi Arm, Single Ctr Study to Evaluate Safety & Tolerability of Escalating Doses of Autologous T Cells Modified With Lentiviral Vectors Expressing High Affinity Gag-specific TCRS in HLA-A02 Patients With HIV

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • To determine optimal dose and to evaluate the safety and tolerability of the study drug. [ Time Frame: 3 years from end of study ] [ Designated as safety issue: Yes ]
  • To monitor for delayed adverse events associated with lentiviral vector gene transfer (RCL and insertional oncogenesis) [ Time Frame: 3 years from end of study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To determine the antiviral effects of WT‐gag‐and α/6‐gag‐ TCR transduced cells in patients with low and high antigen load (presence and absence of viremia) [ Time Frame: 3 years from end of study ] [ Designated as safety issue: Yes ]
  • To monitor engraftment of vector modified cells in the peripheral circulation [ Time Frame: 3 years from end of study ] [ Designated as safety issue: Yes ]

Enrollment: 2
Study Start Date: November 2009
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a WT-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
Biological: WT-gag-TCR modified T cells
Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
Other: STI or Drug Holiday
Subjects will stop taking antiviral medications for 16 weeks.
Experimental: Arm 2
Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a α/6-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
Biological: α/6-gag-TCR modified T cells
Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
Other: STI or Drug Holiday
Subjects will stop taking antiviral medications for 16 weeks.
Experimental: Arm 3
Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir >200. Subject will undergo an 16 week treatment interruption during which a single infusion of WT-gag-TCR modified autologous T cells at 8 weeks post STI.
Biological: WT-gag-TCR modified T cells
Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
Other: STI or Drug Holiday
Subjects will stop taking antiviral medications for 16 weeks.
Experimental: Arm 4
Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir of >200. Subject will undergo a 16-week treatment interruption during which a single infusion of α/6-gag-TCR modified autologous T cells at 8 weeks post STI.
Biological: α/6-gag-TCR modified T cells
Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
Other: STI or Drug Holiday
Subjects will stop taking antiviral medications for 16 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Karnofsky Performance of 80 or higher
  • HLA-A2 Positive
  • Chronic HIV-1 infection
  • On stable HAART regimen (with no changes within 4 weeks of study entry)
  • Willing to undergo a limited treatment interruption of antiretroviral medication
  • CD4+ T cell count ≥450 cells/mm3
  • Documented CD4 nadir of ≥200 cells/mm3
  • Undetectable HIV-1 RNA
  • ARMS 1 and 2 only, at least a singe documented historic viral load set point reading
  • Lab Values: Hgb≥10 males; ≥9.5 females ; ANC≥1000/mm3 ; Platelets≥1000,000/mm3 ; Creatinine≤1.5 mg/dL ; AST, ALT ≤ 2.5xULN

Exclusion Criteria:

  • Current or prior AIDS diagnosis
  • Previous participation in any gene therapy using an integrating vector (subjects treated with Placebo will not be excluded)
  • History of cancer or malignancy (allowed to have successfully treated basal cell or squamous cell carcinoma of the skin)
  • Have history or current exam indicative of active or unstable cardiac disease or hemodynamic instability
  • Have history or current exam indicative of bleeding diathesis
  • Previous treatment with any HIV experimental vaccine within 6 months prior to screening
  • Use of chronic corticosteroids, hydroxyurea or immunomodulating agents such as IL2, interferon alpha, interferon gamma, granulocyte colony stimulating factors within 30 days prior to study entry (inhaled steroids are not exclusionary)
  • Currently breast feeding, pregnant or unwilling to use acceptable methods of birth control
  • Use of aspirin, dipyridamole, warfarin or any other medication that is likely to affect platelet function or other aspects of blood coagulation during the 2 week period prior to leukapheresis
  • Active drug or alcohol use/dependence
  • Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry
  • Receipt of a vaccination within 30 days prior to study entry
  • Have a known allergy or hypersensitivity to human serum albumin, DMSO or Dextran 40
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00991224

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
Adaptimmune
  More Information

Additional Information:
No publications provided

Responsible Party: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00991224     History of Changes
Other Study ID Numbers: 810108
Study First Received: October 6, 2009
Last Updated: February 20, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Pennsylvania:
HIV
HIV therapeutic vaccine

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on April 17, 2014